Black Box Warning Removed: A Critical Update on Hormone Replacement Therapy (HRT)
This is a public announcement regarding the recent removal (November 2025) of the U.S. Food and Drug Administration (FDA) "black box" warning on menopausal hormone therapies (HRT).
Menopausal hormone therapies, commonly referred to as HRT, are approved to provide relief from common and debilitating menopause symptoms, such as hot flashes and night sweats.
For over 20 years, women have been avoiding this life-changing therapy due to overstated warnings about the risk of HRT and breast cancer. Women may be under-utilizing approved therapies that can alleviate menopause symptoms and improve their health because of the past FDA "black box" warnings.
The agency’s decision to remove the warning is a significant step:
Reduced Fear and Alignment with Data: For many women without a history of cancer, this FDA change is intended to reduce fear and align with current data.
Benefits for Healthy Women: For healthy women, particularly those under age 60 or within 10 years of menopause onset, the benefits of using systemic HRT for menopausal symptoms can outweigh the risks.
Understanding HRT: Bioidentical vs. Non-Bioidentical Estrogens
The widespread concern about HRT was largely influenced by the Women's Health Initiative (WHI) study, a landmark study done in 1992.
WHI Study: The study used non-bioidentical (aka non-human estrogen) replacement, specifically conjugated equine estrogens (CEE).
Modern Practice: While CEE is still available, modern practice often favors 17β-estradiol, which is chemically identical to the estrogen naturally produced by the human ovaries (often called "bioidentical").
It is important for women to know the distinction between these different forms of estrogen when considering their treatment options.
Modern hormone replacement therapy (HRT) provides a wide range of benefits that extend beyond simply stopping hot flashes. When started within 10 years of menopause or before age 60 (the "window of opportunity"), the benefits are most pronounced.
1. Relief of Menopause Symptoms
HRT remains the most effective treatment for the most common symptoms:
Vasomotor Symptoms: It reduces the frequency and severity of hot flashes and night sweats by up to 75%.
Sleep and Mood: By eliminating night sweats and stabilizing hormone levels, HRT can significantly improve sleep quality and reduce irritability, anxiety, and "brain fog."
Genitourinary Health: It alleviates vaginal dryness, itching, and pain during intercourse. It also helps with urinary symptoms like urgency and recurrent UTIs.
2. Long-Term Health Protection
Beyond symptom relief, HRT offers several protective benefits for aging:
Bone Health: It is FDA-approved to prevent osteoporosis. It maintains bone density and has been shown to reduce the risk of hip and vertebral fractures by up to 50%.
Heart Health: For women who start HRT early in menopause, some studies suggest a 30% reduction in death from cardiovascular events. Estrogen helps maintain healthy blood vessels and improves lipid profiles (lowers LDL, raises HDL).
Metabolic Benefits: HRT can help reduce the accumulation of visceral (belly) fat and may lower the risk of developing type 2 diabetes by improving insulin sensitivity.
Disease Risk Reduction: Long-term use has been associated with a lower risk of colorectal cancer and may potentially offer cognitive protection against Alzheimer's disease, though this area is still being heavily researched.
3. "Bioidentical" Advantages
Using modern micronized progesterone (rather than synthetic progestins) provides additional benefits:
Better Sleep: It has a mild sedative effect that helps with insomnia.
Mood Stability: It tends to have fewer negative side effects on mood compared to older synthetic versions like MPA.
It is crucial to understand that this labeling change does not apply to all individuals.
The American Society of Clinical Oncology (ASCO) cautions that systemic hormone replacement therapy remains contraindicated for people who previously had:
Breast cancer, particularly those with hormone receptor-positive disease.
Other estrogen-responsive cancers (for example, certain gynecologic cancers).
This is due to an increased risk of cancer recurrence.
For breast cancer survivors whose genitourinary symptoms do not respond to non-hormonal treatments such as vaginal lubricants and moisturizers, low-dose vaginal estrogen remains a good option after discussing the relative risks and benefits with their oncology professional.
If you would like to learn more about this topic I advise you to check out https://peterattiamd.com/rachelrubin/
This is for informational purposes only. For medical advice or diagnosis, consult a professional.